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Substantial progress has been made in the field of cardiovascular tissue engineering with an ever
increasing number of clinically viable implants being reported. However, poor cellular integration of
constructs remains a major problem. Limitations in our knowledge of cell/substrate interactions and
their impact upon cell proliferation, survival and phenotype are proving to be a major hindrance.
Advances in nanotechnology have allowed researchers to fabricate scaffolds which mimic the natu-
ral cell environment to a greater extent; allowing the elucidation of appropriate physical cues which
influence cell behaviour. The ability to manipulate cell/substrate interactions at the micro/nano scale
may help to create a viable cellular environment which can integrate effectively with the host tissue.
This review summarises the influence of nanotopographical features on cell behaviour and provides
details of some popular fabricating techniques to manufacture 3D scaffolds for tissue engineering.
Recent examples of the translation of this research into fabricating clinically viable implants for the
regeneration of cardiovascular tissues are also provided.
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1. INTRODUCTION
Approximately 1 in 3 American adults are thought to suf-
fer from one or more forms of CVD. In addition to the
morbidity and mortality associated with CVD, there is
also a significant economic burden, estimated to be over
$300 bn in 2009. With the continuing social trend towards
obesity, in the United States as well as the rest of the
world, this problem is only likely to be exacerbated. CVD
are the diseases of the heart and blood vessels. The main
cause of death in patients with CVD is often myocardial
infarction due to acute ischemia caused by occlusions of
the vessels supplying nutrients and oxygen to the heart.
The cell death caused by ischemia is irreversible. With the
shear paucity of treatment options available to clinicians
for treating these degenerative diseases the concept of tis-
sue engineering (TE) emerged.
TE aims to repair or regenerate damaged tissue by cul-
turing cells harvested from the patient or donor onto a
∗Author to whom correspondence should be addressed.
suitable material which is then implanted in the patient’s
body at the appropriate anatomical location.1 With the cells
successfully delivered to the desired location, the hope
is that they will integrate with the local tissue with the
scaffold gradually degrading. Alternatively, the scaffold is
directly implanted into the body, stimulating endogenous
cells and the surrounding tissue to mature and proliferate
on the template itself, resulting in in vivo tissue regener-
ation. Both tissue engineering paradigms rely heavily on
novel biomaterials – which can range from natural macro-
molecules, synthetic polymers, ceramics, and various com-
binations of these material types – to tailor the physical,
chemical, structural, and biological properties to achieve
the desired clinical outcome.
The ability to develop and maintain large masses of
viable and functional cells is a complex process. Precise
control over cell phenotype, integration, function, prolifer-
ation and differentiation potential of the implanted device
is a multifaceted challenge. A range of factors have been
implicated in controlling cell behaviour which include, but
are not limited to, endogenous and exogenous mechanical
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forces, biomaterial surface chemistry and environment,
and soluble pharmacological factors.2–5 Whereas the first
generation of biomaterials aimed to merely illicit a min-
imal immune response and provide functional support;
the next generation of materials can be tailored to meet
specific needs for individual applications. Biomaterials
promote tissue regeneration by providing the physical
space-porosity of scaffold-for cells to attach, migrate, pro-
liferate and differentiate. The 3 dimensional (3D) archi-
tecture plays a critical role in maintaining the appropriate
cell phenotype; it regulates the space available for cells to
grow, mass transport via diffusion, mechanical properties
of the scaffold and the cell-substrate interactions. The sur-
face morphology or topography is known to significantly
affect cellular response on biomaterials and thus tissue for-
mation and function.6
In the native tissue, cells are in contact with the extra-
cellular matrix (ECM) which provides cells with biophys-
ical cues which include specific surface chemistry and a
3D topography.78 Whilst single cells are typically tens
of micrometers in diameter, subcellular structures such as
cytoskeleton elements, transmembrane proteins and filopo-
dia are on the nanometer scale. Furthermore, the ECM
consists of nanostructured grooves, ridges, pits and pores
and fibrillar networks composed mostly of collagen and
elastin fibres with diameters ranging from 10–300 nm sug-
gesting a regulatory role for these features.910
By engineering scaffolds at the micro and nano scale;
highly precise reactions, at the cellular and molecular
scale, can be stimulated allowing more control over cell
function.11 Scaffolds can be further functionalised with
various pro-angiogenic and ECM modifying factors which
can be released in a controlled spatio-temporal manner to
modify both host and transplanted cell response.1213 The
principle paradigm being that the scaffold can contain spe-
cific chemical and structural information that can control
cell behaviour and tissue formation.
The aim of this review is to briefly summarise the
role of nanomaterials in cardiovascular TE. The impact
of nano-scale surface topography on cell behaviour will
he highlighted. Fabrication techniques which can be used
to manufacture TE scaffolds, at the nano-scale, provid-
ing greater control over cellular behaviour, will be dis-
cussed. Finally, recent examples of the applications of
nanomaterial scaffolds in the cardiovascular TE field will
be provided particularly focussing on vascular, heart valve
and myocardium regeneration. Whilst nanomaterials have
found uses elsewhere for drug delivery and controlled
release applications these will not be discussed here and
have been reviewed extensively elsewhere.14
2. NANO-SCALE CONTROL OF CELL
BEHAVIOUR
Numerous studies have alluded to the fact that surface
topography impacts cell behaviour; however, the exact
mechanism remains unclear and is still being actively
investigated. Advances in nanotechnology have allowed
researches to create structures from the atomic to macro-
molecular scales in a controlled manner allowing the
systematic investigation into cell behaviour. A number
of techniques have been utilised ranging from chemical
vapour deposition, colloidal lithography, e-beam lithogra-
phy and photolithography – a thorough review of this liter-
ature is beyond the scope of this review but can be found
elsewhere.15–17
The dimension and type of surface feature is an impor-
tant parameter in regulating cell adhesion and spreading
and subsequently gene expression, proliferation and differ-
entiation. The influence of surface protrusions on primary
cardiomyocytes isolated from Sprague-Dawley rats was
evaluated using well defined nanopillar array of polyethy-
lene glycol (PEG) hydrogel.18 Ultravoilet assisted cap-
illary lithography was used to fabricate highly uniform
pillars ∼150 nm wide and ∼400 nm high. Cell adhesion
was found to be significantly enhanced on the nanopil-
lars compared to the bare control. Various elements of the
cytoskeleton were seen to protrude to a greater extent on
the pillared surface compared to the bare control with car-
diomyocytes cultured on the pillars retaining their conduc-
tive and contractile properties.
Human mesenchymal stem cells (hMSC) were used to
study the effect of protrusion height on various cellu-
lar functions; cell adhesion, spreading, cytoskeletal forma-
tion and differentiation was investigated using anodized
titanium surfaces.19 By varying the anodizing voltage;
surfaces with controlled protrusions, rather than random
surface roughness, were created allowing insight into the
exact role of topography on cellular response. hMSC adhe-
sion was greater on the structured surface, with protru-
sions 15 nm in height, compared to the planar control but
was found to decrease with further increasing protrusion
height. Cell response was also greatest on the 15 nm pil-
lared structure with the mean area of cell spreading nearly
twice that of the control.
A similar trend was observed for endothelial cells cul-
tured on 13 nm islands producing highly spread cell
morphologies containing a well-defined cytoskeleton.20
Polymer islands 13, 35 and 95 nm in height were pro-
duced through polymer demixing of polystyrene and poly
(4-bromostyrene). Their results suggested that the 13-nm
island substrate produced the most acute response and the
strongest effect on accelerating cell spreading compared
with other nanotopographies studied.
In addition to protrusions; pits and pores have been
implicated in regulating cell behaviour and function on
the aortic heart valve and vascular system.2122 The diam-
eter, spacing and symmetry of pits have been shown to
induce a variety of effects on cell adhesion.23 Introduc-
ing a degree of disorder to the pit or pore arrangement
appears to improve cell adhesion and function.24 Shallower
pits seem to induce greater cell spreading and attachment
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than deep pits or flat surfaces: pits smaller than 30 nm
formed focal adhesion structures (paxillin-actin) and acti-
vated focal adhesion kinases to a significantly greater
degree than the flat surface control or the surface with pits
in excess of 30 nm.25 It is postulated that surface features
with a maximum z axis dimension (height or depth) of
50 nm may inhibit the formation of focal adhesion sites
necessary for integrin mediated adhesion to substrates.26–28
The impact of nanoscale grooves upon cell geometry and
the expression of a cell–cell coupling protein of cardiac
tissue constructs has been elegantly demonstrated using a
capillary lithography based approach.29 Neonatal rat ven-
tricular myocytes were cultured on a nanopatterned PEG
hydrogel containing grooves 50 nm wide, 200 nm high and
a ridge of 150 nm. The ridges and grooves influence cell
behaviour heavily leading to highly anisotropic cell arrays
guided by the underlying nanoridges. Filopodial extension
in the groove results in adhesion proteins and actin fila-
ments becoming aligned parallel to the groove direction;
with the organisation of actin filaments or microtubules
being identified as the first step in contact guided cell
alignment. However, when pharmaceutical agents were
deployed to destroy actins or microtubules; cells still
displayed contact guidance with a positive correlation
between focal adhesion proteins and cell alignment.30
The dimension of the groove is critical in influencing cell
behaviour; however, no clear consensus has been reached
regarding the absolute dimensions of grooves for optimal
cell control (Fig. 1). It is likely to be cell specific and
dependant on whether cell-cell contact has been achieved
or if cells are being cultured in isolation. Groove depth
appears to be an important parameter; shallow nanogratings
result in an increased interfacial area leading to improved
cell adhesion and spreading with grooves as small as 35 nm
deep shown to induce cell alignment.31 This effect dimin-
ishes when feature size becomes negligible (<35 nm).
Fig. 1. Schematic illustration of cell response to a grooved substrate. a)
Cells align and elongate along the direction of the groove. b) Grooved
substrate leads to an increased interfacial area resulting in improved adhe-
sion and spreading. c) Increased depth results in cells unable to reach the
groove leading to elongation in the direction of the groove but no spread-
ing perpendicular. d) Reducing the width of the groove allows the cells to
bridge over the gap. e) Increased width results in cells sensing a planar
surface with a step, diminishing the impact of topography on cell function.
If the depth of groove is increased then the cell can no
longer reach the groove resulting in elongation in the
direction of the ridge but retardation in the direction per-
pendicular. This can lead to a smaller cell size result-
ing in slower proliferation rate and even apoptosis.3233
Increasing the groove or ridge width excessively will lead
to the cells sensing each ridge/groove as a planar sur-
face separated by a step which neither initiates integrin
activation and clustering nor increases the surface area to
facilitate focal adhesion formation. In contrast, decreas-
ing the groove width whilst increasing the groove depth
leads to cells bridging the ridge without descending into
the groove. Epithelial cells cultured on grooves 150 nm
deep formed bridges over grooves 330 nm–950 nm wide
yet descended into grooves 2.1 m wide.34
The cell specificity of responses to substrate topography
has been demonstrated in EC, whereby EC from different
anatomical locations (human umbilical vein endothelial
cells (HUVEC), human dermal microvascular endothe-
lial cells (HmVEC-d), human aortic endothelial cells
(HAEC) and human saphenous vein endothelial cells
(HSaVEC-c)) were cultured on topographically patterned
substrates resulting in unique and distinct behaviour for
each cell type.35 Whilst important advances have been
made with ample evidence available establishing the con-
nection between nanostructures and cellular response, the
mechanistic understanding of this relationship is still lack-
ing. Many studies are still qualitative; coupled with vari-
ations in cell types, disparities in nanoscale features and
different experimental protocols all make it difficult for
in-depth analysis.
3. SCAFFOLD ASSEMBLY AND
FABRICATION
In addition to the surface morphology of the scaffold; for
a tissue engineered construct to be successful it must be
able to maintain a large mass of viable cells in a 3D
environment. Whereas 2D biomaterials are a potent tool
to elucidate the regulatory mechanisms governing cell-
substrate interactions; 3D structures allow the reconstruc-
tion of complex tissues. Integrin binding and the formation
of focal adhesions in 3D tissues is substantially different
from their binding and formation in 2D culture with 3D
structures in vivo strongly influencing cell shape, affect-
ing the differentiation process (Fig. 2).3637 To achieve this
aim, a high surface area-to-volume ratio and a porous
environment for mass transport of nutrients and metabolic
waste products is required. The coupling of a porous
scaffold with nanostructured substrate offers a powerful
tool for regenerating tissue, allowing the manufacturing of
scaffolds which mimic the ECM in dimension and scale.
These biomimetic scaffolds can be produced primarily
through three manufacturing techniques: electrospinning,
phase separation and self assembly, with Table II provid-
ing a summary of the main features of these techniques.
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Fig. 2. Cell adhesion and spreading on 2 dimensional (A) and 3 dimen-
sional (B) substrates. Cells binding to 2D substrates flatten and spread
whereas a 3D substrate provides many more adhesion sites for the for-
mation of focal adhesions, due to the increased surface area available.
The cell senses its environment and responds via a series of intra and
extra cellular signalling which can affect its motility, function and spread-
ing. The more biomimetic, 3D environment, is thought to be essential
in maintaining a large mass of clinically viable cells with the correct
phenotype required for the formation of functional tissue.
3.1. Electrospun Fibres
A highly versatile and inexpensive method of mim-
icking the native ECM fibrous network is through
Table I. Influence of nanoscale surface features on cell behaviour. Keys: PGS: polyglycerol sebacate; Ti: titanium; PMMA: poly(methyl methacrylate);
TiO2: titanium dioxide; Al2O3: alumina; PCLLGA: poly(-caprolactone-r-l-lactide-r-glycolide); HSC: hematopoietic stem cells.
Substrate Cell type Nanoscale feature and size Comments Ref
PEG Primary
cardiomyocytes
Well defined array of pillars 150 nm wide and
400 nm high
↑cellular adhesion, retained their
conductive and contractile properties
[18]
PGS C2C12 muscle cells Doubled ridged gratings 10 m wide × 10 m
deep × 10 m spaced at 170 m intervals and
pores with dimensions 150 m×150 m and
280 m × 150 m
Cells penetrated pores and aligned
parallel to gratings.
[115]
Ti hMSC Surface protrusions 15 nm in height, 28 nm
wide and 40 nm spacing
↑cellular adhesion and spreading [19]
PS and poly
(4-bromostyrene)
EC Islands 13 nm, 35 nm and 95 nm in height ↑cellular adhesion and spreading [20]
PMMA hMSC Pits 100 nm deep and 120 nm in diameter in
both ordered and disordered arrays.





Grooves 50 nm wide, 200 nm high and a ridge
of 150 nm
↑cellular adhesion, spreading and
function
[29]
Ti EC Grooves 150 nm in height and 750 nm pitch ↑cellular adhesion [116]





Al2O3 SMC 200 and 10 nm pores no response in cell adhesion, an alteration
in cell morphology, ↑cell proliferation for
cells grown on 200 nm-pore surfaces than
on 20 nm-pore surfaces
[118]
PCLLGA Human vSMC Microchannels 160 m long, 300 m wide
with gaps of 40 m
Cells proliferate well initially, indicative
of synthetic phenotype, but change to a
contractile phenotype upon confluence.
[119]
electrospinning.3839 In this method (Fig. 3), an electro-
static force is applied between the positively charged poly-
mer solution and the substrate. When the electrostatic
charge overcomes the surface tension of the droplet, a
polymer jet is formed (Fig. 3(A)), which then elongates
and thins. As the solvent evaporates from the jet, an elec-
trically charged polymer is left behind. These solidified
fibres are then collected on a grounded surface (Fig. 3(B)).
Due to the simplicity of this method, electrospinning has
been widely used by a variety of research groups. A range
of materials – biodegradable and non-biodegradable, syn-
thetic and natural polymers – can be electrospun, rang-
ing from silk fibroin and collagen to polyurethanes and
polyesters.40–42 This technique allows for the control of
thickness, composition and porosity of nanofibre meshes
with a relatively simple experimental set up. Fibres with
a diameter of a few micrometers down to as small as
∼3 nm can be developed, resulting in significantly larger
surface areas.43 Porosities in excess of 90% and pore
sizes ranging from a few microns to tens of microns can
be produced resulting in effective cellular infiltration and
allowing the effective mass transport of nutrient and waste
products to and from cells.4445 Blends of different materi-
als can be used to augment the mechanical and/or biolog-
ical behaviour of the scaffold.4647 Furthermore, the fibres
can be functionalised with a wide range of ECM proteins
and bioactive agents resulting in a scaffold which has ECM
like physical and biochemical properties.4647 Through pro-
viding a more biomimitec environment for cells to grow
upon; cell adhesion, proliferation, migration and differen-
tiation were all shown to improve on electrospun fibres for
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Table II. Common scaffold processing techniques for tissue engineering.
Fabrication
method
Feature size Advantages Disadvantages
Electrospinning39 ≥3 nm Highly versatile, range of sizes available, cheap
and experimentally simple set-up, can be applied
to a number of materials
Can only create fibres, not nanopatterned




Fibre size 50–500 nm, pore
size range from nm–m
Highly porous, simple experimental set-up,
versatile, can combine with other techniques for
greater control over macro and micro structure.
Permits incorporation of bioactive agents.
Randomly orientated fibres and pores.
So far, no reports of organised fibres and






3-dimesional structures, molecular control of
substrate, versatile, can be used with sensitive
biomolecules, range of morphologies and sizes
available, offers properties and functionalities not
possible with conventional organic synthesis
The non-trivial engineering of molecules
that will self-assemble, mechanical stability,
degradation not heavily studied. Longer
prep time in certain circumstances
a variety of cell types.48–51 Cells tend to grow in the direc-
tion of the fibre alignment which is particularly pertinent
for EC as it mimics the morphology of EC in vivo under
blood flow.
3.2. Phase Separation
Phase separation involves the thermodynamic mixing of a
homogenous polymer-solvent solution into a polymer-rich
and polymer-poor phase, usually achieved by exposing
the polymer-solvent solution with another immiscible sol-
vent or by cooling the solution. A wide variety of
porous structures, including nanofibrous structures, can
be manufactured with this technique through the fine-
tuning of kinetic and thermodynamic parameters.5253 Pro-
cess parameters such as polymer concentration, temper-
ature, the types of polymers and solvents all influence












Fig. 3. Schematic Diagram of the electrospinning process for the pro-
duction of polymeric nanofibres. A polymer solution is held in a syringe
and pumped through a metal needle. A high voltage supply is connected
to the needle, producing a fine jet of polymer solution (A). This dries
out in transit, resulting in fine fibres which are collected on an earthed
target (B).
increase in polymer concentration and/or viscosity all lead
to a decrease in porosity, and thus an increase in mechan-
ical properties. A major advantage of phase separation
method is its simplicity and the lack of need for any spe-
cialised equipment. As it is a mould based technique, scaf-
folds with complicated shapes, or pore structures can be
manufactured relatively easily (Fig. 4). The phase separa-
tion process resembles a porous structure embedded in a
3D fibrous network (Fig. 5). The fibrous network consists
of fibres ranging form 50 to 500 nm and display porosi-
ties up to 98%.55 The versatility of the phase inversion
method allows itself to be combined with other process-
ing techniques, such as particulate leaching or 3D printing,
to design complex 3D structures with well-defined pore
morphologies.5657 By combining phase separation with a
second manufacturing technique; control over the macro-
pore structure can be administered, in addition to the gen-
eration of ECM resembling nanofibres, which can lead to
the more efficient cellularisation of the scaffold and the
mass transport of nutrients and metabolic waste products.
The resulting high surface area-to-volume ratios result
in enhanced protein adsorption and improved cellular
functions including adhesion proliferation and migration.
Fig. 4. Complex anatomical structures of nose and ear produced via
the phase separation process with controlled porosity and mechanical
rigidity using a POSS-Nanocomposite polymer developed and patented
by authors.
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Fig. 5. 3-dimensional porous POSS-PCU scaffolds produced by phase
separation. A) Cross section of scaffold demonstrating interconnected
nature of the pores. B) Surface displaying a porous, textured and rough-
ened surface of scaffold.
Both synthetic and natural polymers have been used in this
way to manufacture 3D scaffolds.5859
3.3. Molecular Self Assembly
Molecular self-assembly is unique in its ability to form
a wide range of diverse nanostructures. It involves the
spontaneous organisation of molecules into more ener-
getically stable conformations favoured by hydrophobic,
Van der Waal and electrostatic interactions as well as
hydrogen bonding resulting in a final supramolecular struc-
ture ordered on multiple length scales.60–62 This technique
allows for the molecular control of the materials whilst
fabricating 3D scaffolds providing the potential to mimic
the complex signalling machinery of the ECM. Several
critical structural features are required for self-assembling
molecules; for instance, long alkyl tails are required to
confer the hydrophobicity which drives self-assembly;
a long enough linker region which provides the flexibility
to the hydrophilic head; and cysteine residues which can
polymerise the reaction via disulfide bonds.63 An elegant
example of collagen, a key component of the native ECM,
self assembly was demonstrated using peptide amphil-
philes held together in a staggered array by disulfide
bonds.64 The hydrophobic head of the peptide amphiphiles
formed the triple helical structure whilst the hydrophilic
tail reorganises and stabilises the self assembled 3D struc-
ture of the scaffold. Scaffolds can be functionalised with
self-assembled peptide amphiphiles which act as cell adhe-
sive ligands such as Tyr-Ile-Gly-Ser-Arg (YIGSR) and
Val-Ala-Pro-Gly (VAPG).65 The attachment of these pep-
tides can significantly increase the adhesion, spreading
and proliferation of EC. It was also found that these
particular ligands reduced platelet adhesion compared to
the collagen control, which for vascular applications, is
highly desirable. Self-assembly can be initiated in a num-
ber of ways including pH, concentration, temperature,




The field of cardiovascular tissue engineering is expanding
at an exponential rate. The following section will aim to
provide recent of examples of the use of biomaterials, both
synthetic and natural, structured at the nano-scale in the
regeneration of vascular, valvular and myocardial tissue,
summarised in Table III.
4.1. Vascular
Diseases of the blood vessels – arteries, veins and lymph
vessels – are a principle component of CVD and a major
cause of mortality. In severe cases the only treatment
option is for bypass surgery – re-routing blood round the
blockage. Whilst synthetic grafts have proven to be suit-
able for replacing large calibre vessels, patency rates have
been largely disappointing in the replacement of vessels
5 mm or smaller in diameter.70 Autologous vessels remain
the conduit of choice for small diameter applications; how-
ever, they are not always available and failure rates remain
high. Failure has been attributed primarily to thrombus
formation, due to the inherent thrombogenicity of the syn-
thetic surface, and intimal hyperplasia as a result of a
mechanical mismatch between the elastic artery and rigid
graft.7172
For a cardiovascular graft to be patent in the long term
it must resist narrowing of the lumen by intimal thickening
and possess thromboresistant properties with a functional
endothelium. The endothelium is the thin layer of cells
that line the interior surface of blood vessels, maintaining
vessel integrity with various dynamic mechanisms prevent-
ing intimal hyperplasia and thrombosis. Materials which
promote the adhesion and growth of endothelial cells are
much sought after. A number of studies have demonstrated
that EC adhesion growth and function is improved on
rough surfaces.7374 Poly(lactic-co-glycolic acid) (PLGA)
was treated with sodium hydroxide (NaOH) and cast onto
silastic moulds resulting in random and uncontrollable
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Table III. Examples of nanomaterial based cardiovascular tissue engineering strategies.
Fabrication
method Scaffold material Feature size (nm) Cell type Comments References
Chemical etching PLGA ∼200 EC and SMC ↑ cell density, ↑ cell function [74–76]
Electrospining PCL ∼250 Primary
cardiomyocytes
↑ expression of cardiac specific
proteins
[105, 106]
PGA ∼5 Cardiac stem cells ↑ cellular adhesion [107]
Decellularised heart
vale+poly-4-hydroxybutyrate
— MSC ↑ ECM deposition [96]
Polyurethane ∼880 EC Functioning EC attachment
successful
[80]
Gelatine, elastin, PCL and
poliglecaprone composite
0–2400 EC EC had normal function, ↓ reduced
platelet adhesion
[120, 121]





↑ cell adhere, spread, and
proliferate. ↓ macrophages and




100 EC Confluent layer of EC, maintained
phenotypic expression of
PECAM-1. Patent after 7 weeks
in vivo in rabbit.
[85, 123]
Phase separation PLGA 120–240 m A10 cell line Collagen modified scaffold resulted
in greatest cell adhesion. Cells
aligned along microtubules.
[124]
Poly(ester rethane)urea 12–232 m Muscle-derived
stem cells
Confluent layer of von Willebrand
Factor-positive cells observed
[125]
Self-assembly Fibrin gel — human
microvascular
endothelial cells
Magnetically guided assembly. Cell










X is a hydrophobic amino acid and




surface features 200 nm in size. Both vascular smooth
muscle cell (SMC) and EC densities were improved on
treated PLGA surfaces possibly due to an increase in the
adsorption of fibronectin and vitronectin, key proteins for
mediating cell density on nanostructured PLGA.75 Cellu-
lar function was also shown to improve; cells grown on
nano-structured surfaces were observed to have very long
filopodia protruding from the cell body allowing the cell to
scout the surrounding area and interact with the nanometre
structures.76 Furthermore, an increase in matrix metallo-
proteinases (MMPs), enzymes linked to cell movement and
adhesion to substrata, was observed from the supernatant
of EC cultured on nano-structured surfaces.77 EC migra-
tion was studied on rough surface using a nanocompos-
ite of polyurethane doped with gold nanoparticles as a
model system.78 The rougher surface resulted in activa-
tion of the focal adhesion kinase (FAK) and P13K/AKT
signalling pathways, resulting in cytoskeletal changes and
an upregulation of eNOS, indicating greater EC migration
and proliferation.
Tubular scaffolds for tissue engineering a blood ves-
sel have been manufactured from materials as diverse
as silk fibroin to poly(L-lactide-co--caprolactone) and
polyurethanes through electrospinning.79–81 These con-
structs are often limited by the size in which they can
be manufactured leading to poor burst strengths. However,
by aligning the nanofibres, greater mechanical strength
and modulus of nanofibre can be achieved and some
degree of control over direction of cell growth can be
administered.8283 Further functionalization of the scaf-
fold with ECM proteins such as gelatin and collagen,
appeared to improve EC and SMC adhesion, growth and
functionality.84 The expression of EC specific surface
markers such as von Willebrand Factor (vWF), CD31,
CD54 and CD106 indicate normal cell function is main-
tained in vitro.85 Electrospinning can be further utilised to
overcome the inherent problem of cellular infiltration into
scaffold pores, by concurrently electrospraying cells whilst
electrospinning the polymer.86 SMC’s were uniformly inte-
grated into the scaffold both radially and circumferentially
using this technique. The scaffold appeared to be strong
and flexible with reasonable dynamic compliance and burst
strength values.
Our lab made use of the phase separation method
to manufacture a small diameter vascular graft from a
novel nanocomposite, polyhedral oligomeric silsesquiox-
ane poly(carbonate-urea)urethane (POSS-PCU) (Fig. 6).87
The amphiphilic, lipid like, nature of the POSS-PCU
nanocomposite resulted in it having anti-thrombogenic
properties by both repelling platelet surface adsorption and
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Fig. 6. POSS-PCU vascular graft produced by the phase separation
method and implantation of this graft in sheep carotid artery, undergoing
pre-clinical trials.
lowering the binding strength of platelets to the nanocom-
posite polymer.88 The improved tensile strength of POSS-
PCU allows the fabrication of a porous graft capable of
endothelialisation, without compromising its mechanical
integrity. The conduits produced through phase separation
have unique viscoelastic properties resulting in pressure-
responsive radial compliance characteristics similar to that
of biological microvessels.89 This would minimise compli-
ance mismatch between graft and host artery over physio-
logical pressure ranges, thereby reducing the incidence of
intimal hyperplasia.90
As blood vessels are load baring structures, their
mechanical properties are critical for a successful therapy.
A major drawback of many tissue engineering constructs
is insufficient radial strength leading to poor bursting pres-
sures. Interestingly, blood vessels constructed through the
self assembly approach result in superior mechanical prop-
erties. The self assembly approach consists of culturing
human umbilical vein SMC (hUVSMC) and dermal fibrob-
lasts (hDF) in vitro into a cell sheet which is then rolled
around a mandrel and cultured to form a tissue engineering
blood vessel with a similar medial and adventitial structure
to the native vessel.91 EC cells can then be seeded onto
the luminal surface to form a functioning endothelium.
The vessels produced through self-assembly have the ten-
sile strength to be used as a viable graft; and compliance
values, over the physiological loading range, comparable
to the native vessel and are thus a promising candidate for
clinically viable TEBV.92 Indeed, self-assembled TEBV
have been shown to be antithrombogenic and mechanically
stable in vivo for a period of 8 months in a rat model
resulting in the formation of a confluent endothelium and
vasa vasorum formation.93
4.2. Heart Valve
Heart valve prostheses are amongst the most widely used
biomedical devices and face an ever growing demand.94
However, currently available prosthetic valves lack the
ability to grow, repair and remodel in an in vivo environ-
ment; in addition to problems associated with calcification,
thrombosis, tearing and biodegradation.95 A tissue engi-
neered heart valve has the potential to overcome a number
of these drawbacks.
A decellularised heart valve has been proposed as the
ideal scaffold for tissue engineering heart valves as they
provide the natural valve architecture and optimal condi-
tions for cell culturing. There are some major limitations
to the use of decellularised scaffold; principle amongst
them is the loss of all mechanical integrity. To counter
this problem, a decellularised heart valve was coated with
electrospun poly-4-hydroxybutyrate – a biodegradable bio-
material – and then seeded with mesenchymal stem cells
(MSC).96 The hybrid scaffold displayed improved mechan-
ical properties and the ECM like morphology of the elec-
trospun fibres provides a biomimitec surface for culturing
MSC. The scaffold has been further modified to include
bFGF loaded chitosan nanoparticles in a bid to stimulate
MSC proliferation.97 A significant increase in collagen and
4-hydroxyproline was noted for the bFGF containing scaf-
fold, suggesting that the inclusion of bFGF enhances the
formation of ECM components leading to an improvement
in the mechanical strength of the valve.
A promising, wholly synthetic, heart valve scaffold has
been developed in our lab using POSS-PCU (Fig. 7).98
The addition of the POSS nanoparticle alleviates many
of the traditional problems associated with polyurethane’s;
namely, biodegradation, calcification and, as previously
mentioned, thrombosis. POSS-PCU displayed significantly
improved biodurability and stability when exposed to a
variety of degradative solutions.99 The hydrophobic nature,
and improved mechanical performance, of the POSS-PCU
heart valve also led to reduced calcification when exposed
to calcium solution in a bespoke in vitro accelerated phys-
iological pulsatile pressure system for a period of 31
days.100 Furthermore, the roughened surface morphology
means a greater surface area of polyurethane is avail-
able for adhesion, growth and proliferation of endothelial
cells.101
A hydrogel composed of polyvinylaclohol (PVA) and
bacterial cellulose nanofibers of <100 nm has also been
mooted as a possible biomaterial for tissue engineering
heart valves.102 It was hypothesised that whilst the PVA
would provide the elasticity required by heart valves,
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Fig. 7. A) Trileaflet valve design with complex geometry and additional
reflection on the leaflets to improve performance and durability. B) Pro-
totype valve fabricated from POSS–PCU nanocomposite with a Dacron
suture ring. AFM images of the surface topography of PCU (C) and
POSS-PCU (D). The POSS nanocomposite cage can be seen clearly pro-
truding from the film surface giving the polymer a rough, textured surface
more conducive to endothelialisation.
the introduction of bacterial cellulose would provide the
stiffness; mimicking the role of elastin and collagen,
respectively, in native tissue. The nanocomposite hydrogel
displayed stress/strain behaviour comparable with porcine
aortic heart valves and efforts have been made to optimise
leaflet design through computational simulations.103
4.3. Myocardium
Heart failure contributes to the death of 300 000 people
and leads to over 1 million hospitalisations annually in the
US.104 Cardiac myocytes are terminally differentiated cells
and cannot regenerate following injury. With a chronic
shortage of transplantable hearts, the ability to repair or
engineer myocardium is highly attractive.
Electrospun scaffolds have shown great promise in sup-
porting cardiomyocytes in vitro. The fibres provide sup-
port, analogous to the ECM, by providing isotropic and
anisotropic cues for growth allowing cells to grow into
and pull on the fibres.105 A nanofibrous PCL mesh was
seeded with cardiomyocytes from neonatal Lewis rats and
cultured in vitro for 14 days.106 The mesh started beat-
ing after 3 days and expressed cardiac specific proteins –
-myosin heavy chain, connexin43 and cardiac troponin
I – suggesting that functional contracting cardiac grafts
can be generated. In order to get a dense, 3D graft, with the
ability to provide enough function; individual meshes were
overlaid to create a multilayered, thick graft.45 The authors
reported that the individual layers adhered well and mor-
phological and electrical communication was established
between the layers with the construct beating in sync.
Cell sourcing remains a critical problem as it is difficult
to obtain autologous cardiomyocytes for transplantation.
Cardiac stem cells (CSC), with the ability to differentiate
into cardiomyocytes, hold great promise. CSC were seeded
onto collagen scaffolds incorporating poly(glycolic) acid
nanofibres and were cultured in vitro.107 A greater number
of CSC adhered to the scaffold incorporating the nanofi-
bres than the control with no fibres. An interesting alterna-
tive to the use of cardiomyocytes is the controlled delivery
of granulocytes colony-stimulating factor (G-CSF) to pro-
mote myoblast differentiation towards the myocardiocyte
lineage.108109 By functionalising electrospun fibres with
G-CSF, an ECM mimicking scaffold with the ability to
release G-CSF was produced.110 Cardiomyocyte like phe-
notype was only partially induced in skeletal myoblasts,
however, this study provided an interesting alternative to
currently used approaches in cardiac tissue engineering.
The high surface area and ECM like topography of
electrospun nanofibres has also been utilised for in vivo
regeneration through injectable self assembling peptide
nanofibres.111–114 These self assembled peptide nanofibres
were found to create microenvironments conducive to pro-
genitor cell recruitment within the myocardium.112 A sec-
ondary injection of exogenous cells within the peptide
microenvironment resulted in recruitment of -sarcomeric
actin/Nkx2.5–positive cells. Furthermore, an additional
significant advantage of self-assembling peptides is that
they can be engineered to be incorporate growth factors
and other signalling molecules capable of controlling cel-
lular fate. The controlled release of platelet derived growth
factor (PDGF) from self-assembled peptide nanofibres, for
a period of 14 days, led to reduced cardiomyocyte death
and infarct size following infarction.113 In a similar fash-
ion, the sustained release of insulin-like growth factor-1
(IGF-1), in conjunction with local injections of clonogenic
cardiac progenitor cells, led to a reduction in infarct size
and improved the recovery of myocardial structure and
function.114 Protease-resistant stromal cell derived factor-1
chemokine was anchored to the self-assembled nanofibres
in an effort to attract endogenous stem cells.111 Whilst the
local delivery of chemoattractants for stem cells is a pop-
ular strategy for regeneration, it is often handicapped by
rapid diffusion from the site of injection. Anchoring the
chemokine to the self assembling peptides alleviates this
major drawback. Increased cellular recruitment and cap-
illary tube formation was observed in the test subjects,
in addition to improved systolic function one month after
infarction.
5. CONCLUSIONS
The nanoscale design of biomaterials has led to highly
promising technologies capable of improving surgical
management of tissue loss. Greater control over cellular
interactions at the material interface can be implemented,
and with improvements in cell and developmental biology,
greater control over the human body’s response to exoge-
nous materials can be exerted. Whilst tissue engineering
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approaches to repair or regenerate cardiovascular tissues
hold great potential, they are still in their infancy and
numerous challenges remain to be overcome before they
can become a clinical reality. Suitable cell sources need
to be identified and the rules governing cell growth and
differentiation on biomaterials need to be understood. For
the exciting possibility of tissue engineering the entire
heart, scaffolds capable of providing the necessary flux
of oxygen and nutrients to densely packed cells in whole
organs need to be developed. To overcome these problems,
a multidisciplinary approach needs to be taken with life
scientists working hand in hand with engineers, material
scientists and mathematicians.
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